Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jan;28(1):205-208.
doi: 10.1111/jvh.13394. Epub 2020 Sep 14.

Hepatitis B core-related antigen levels predict recurrence-free survival in patients with HBV-associated early-stage hepatocellular carcinoma: results from a Dutch long-term follow-up study

Boris J B Beudeker  1 , Zwier M A Groothuismink  1 , Robert A de Man  1 , Caroline D M Witjes  2 , Annemiek A van der Eijk  3 , Andre Boonstra  1 , Milan J Sonneveld  1
Affiliations

Hepatitis B core-related antigen levels predict recurrence-free survival in patients with HBV-associated early-stage hepatocellular carcinoma: results from a Dutch long-term follow-up study

Boris J B Beudeker et al. J Viral Hepat. 2021 Jan.

Abstract

Prognosis of hepatitis B (HBV)-associated hepatocellular carcinoma (HCC) is poor due to high rates of HCC recurrence and progression of underlying liver disease. We studied whether serum hepatitis B core-related antigen (HBcrAg) levels could predict HCC recurrence and outcome in HBV associated. Higher HBcrAg levels at HCC diagnosis were independently associated with reduced overall and recurrence-free survival in patients with early, but not advanced, stage HCC.

Keywords: HBcrAg; hepatitis B; hepatocellular carcinoma; survival.

PubMed Disclaimer

Conflict of interest statement

MJS received research support and consultancy fees from Fujirebio. AB received research support from Fujirebio. The other authors report no disclosures.

Figures

Figure 1
Figure 1
Adjusted overall survival (left) and recurrence‐free survival (right) according to HBcrAg level among patients with early‐stage HCC, stratified in terciles: (HBcrAg ≤ 3.0; HBcrAg 3.1‐5.0; HBcrAg ≥ 5.1)
See this image and copyright information in PMC

References

    1. European Association For The Study Of The L . EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69(1):182‐236. - PubMed
    1. Testoni B, Lebosse F, Scholtes C, et al. Serum hepatitis B core‐related antigen (HBcrAg) correlates with covalently closed circular DNA transcriptional activity in chronic hepatitis B patients. J Hepatol. 2019;70(4):615‐625. - PubMed
    1. Cheung KS, Seto WK, Wong DK. Complete title: relationship between HBsAg, HBcrAg and hepatocellular carcinoma in patients with undetectable HBV DNA under nucleos (t) ide therapy. J Viral Hepat. 2017;24(8):654‐661. - PubMed
    1. Sonneveld MJ, van Oord GW, van Campenhout MJ, et al. Relationship between hepatitis B core‐related antigen levels and sustained HBeAg seroconversion in patients treated with nucleo(s)tide analogues. J Viral Hepat. 2019;26(7):828‐834. - PubMed
    1. Tada T, Kumada T, Toyoda H, et al. HBcrAg predicts hepatocellular carcinoma development: an analysis using time‐dependent receiver operating characteristics. J Hepatol. 2016;65(1):48‐56. - PubMed

Publication types

MeSH terms